# Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

> **NCT05156060** · PHASE1,PHASE2 · RECRUITING · sponsor: **Natalie Lockney** · enrollment: 64 (estimated)

## Conditions studied

- Head and Neck Cancer
- Locally Advanced Head and Neck Carcinoma

## Interventions

- **DRUG:** Gabapentin
- **DRUG:** Ketamine

## Key facts

- **NCT ID:** NCT05156060
- **Lead sponsor:** Natalie Lockney
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-24
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156060, "Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05156060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*